Live Breaking News & Updates on Pipeline Objectives|Page 1

Stay updated with breaking news from Pipeline objectives. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022 Aerie Expects to be Cash Flow Break Even During 2024DURHAM, N.C.DURHAM, N.C. (BUSINESS WIRE) Aerie Pharm. ....

United States , Raj Kannan , Hans Vitzthum , Carolyn Mcauliffe , Aerie Pharmaceuticals Inc , Drug Administration , Regulatory Agency , Exchange Commission , European Medicines Agency , Aerie Pharmaceuticals , Second Quarter Glaucoma Franchise Net Revenues , Second Quarter , Net Cash Used Expected , Cash Flow Break Even During , Chief Executive Officer , Quarter Financial Results , Pipeline Objectives , New Drug Application , Webcast Information , Call Time , Dial In Time , Private Securities Litigation Reform Act , Investigational New Drug Applications , Loss Per Share , Adjusted Net Loss Per Share , Sci Advisors ,

Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

First Quarter Glaucoma Franchise Net Revenues of $29.8 Million, up 30% over First Quarter 2021Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 MillionFirst Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter of 2022DURHAM, N.C. (BUSINESS WIRE) Aerie Pharmac. ....

United States , Avizorex Pharma , Peter Lang , Raj Kannan , Gary Sternberg , Hans Vitzthum , Carolyn Mcauliffe , Aerie Pharmaceuticals Inc , Drug Administration , Regulatory Agency , Exchange Commission , European Medicines Agency , Aerie Pharmaceuticals , First Quarter Glaucoma Franchise Net Revenues , First Quarter , Franchise Guidance , Enrollment Second Quarter , Chief Executive Officer , Chief Medical Officer , Chief Financial Officer Peter Lang , Quarter Financial Results , Pipeline Objectives , New Drug Application , Private Securities Litigation Reform Act , Investigational New Drug Applications , Loss Per Share ,